I serve on ICAN's (International Cancer Advocacy Network) board of Advisors representing patients and their families in Texas.
The biosimilars are money saving and have their place, however they need to be properly vetted before being prescribed. This is a good bill and I remarked on its importance.
The biologics are complex and although the biosimilars can save money, it is extremely important that they are not used without the doctor’s knowledge. When the biosimilars have gone through the proper FDA hoops they will be able to be more widely used.
Presenting in front of a committee this Tuesday was a new experience for me! Observing the process on how our government works is fascinating.